Healthcare Providers and Services
Company Overview of N-of-One Therapeutics, Inc.
N-of-One Therapeutics, Inc. provides clinical analysis, curation, and interpretation of a tumor's molecular profile to providers, diagnostic companies, individual physicians, and cancer patients. The company’s solutions include treatment strategy roadmaps, clinical trial matching, and diagnostic strategy roadmaps. Its solutions and services pivot on matching patient-specific tumor molecular profiling data with knowledge on diagnostic technologies and therapeutic options to identify relevant clinical strategies for each patient's unique cancer. The company supports oncologists by delivering content and clinical insights for cancer treatment decisions and diagnostic approaches. N-of-One Therap...
430 Bedford Street
Lexington, MA 02420
Founded in 2007
Key Executives for N-of-One Therapeutics, Inc.
Chairman and Chief Executive Officer
Founder, President, Chief Medical Officer and Director
Vice President of Operations
Compensation as of Fiscal Year 2015.
N-of-One Therapeutics, Inc. Key Developments
N-of-One Launches PrecisionInsights for Cost Effective, Quality Clinical Interpretation of 15-20 Gene NGS Solid Tumor Panels
Oct 6 15
N-of-One, Inc. announced N-of-One PrecisionInsights™, a new clinical interpretation solution specifically designed for small gene panels of 15-20 genes. N-of-One PrecisionInsights™ is a concise, two-page report for each case providing the most recent clinical and scientific evidence specific to the identified genes and variants in the context of the specific cancer sub type. Key attributes include: Turnaround time of one business day; Cost-effective pricing of $65 per report, with a one-time $1,000 implementation; Most up-to-date scientific and clinical evidence in the industry; and Incorporates NCCN guidelines and relevant therapies. As with other N-of-One clinical interpretation solutions, N-of-One PrecisionInsights™ is based on the same foundation of high-quality clinical interpretation: Case- and Disease-Specific: N-of-One interpretation is specific for each cancer subtype. For example, interpretation of a breast cancer case will address the impact of the detected somatic variants in the context of the specific histolopathology of the breast cancer. N-of-One Expertise and Experience: N-of-One’s team of over 30 on-staff PhD scientists and oncologists research and analyze each case to ensure accuracy and actionability. N-of-One’s knowledgebase is recognized as one of the most comprehensive sources of oncology clinical and scientific evidence in the industry.
Spectrum Health Selects N-of-One to Provide Clinical Interpretation for 50-Gene Hot-Spot Solid Tumor Panel
Aug 18 15
N-of-One, Inc. announced that it has signed an agreement with Spectrum Health to provide clinical interpretation for all cases sequenced on Spectrum Health’s 50-gene hot-spot solid tumor panel. The Spectrum Health Cancer Center is focused on delivering individualized care to each cancer patient. A commitment to high-quality care and innovation has made Spectrum Health a regional leader and a referral center for cancer treatment. N-of-One's clinical interpretation provides the relevant scientific and clinical evidence related to the mutation profile of a tumor identified by sequencing, taking into account each patient’s specific molecular profile. This in turn links the clinical and scientific evidence to therapeutic strategies relevant for each patient.
CompanionDx Selects N-of-One’s Cost-effective, High-quality Clinical Interpretation for Targeted Next-generation Sequencing Tests
Jul 22 15
N-of-One, Inc. announced that CompanionDx, a CLIA certified, high-complexity laboratory specializing in integrated genomic solutions, combining diagnostics such as next-generation sequencing, pharmacogenomics and drug monitoring, signed an agreement with N-of-One for N-of-One to provide clinical interpretation for both CompanionDx's focused and comprehensive oncology panels. Financial terms of the agreement are not disclosed. CompanionDx's next-generation sequencing evaluates the DNA in a patient's tumor via a small biopsy sample. The DNA is analyzed for key changes or somatic mutations. When combined with the company's pharmacogenomics testing, which establishes a clear understanding of the patient's potential for metabolizing a drug based on their possible germline variants, CompanionDx can help increase the efficacy of prescribed therapy creating a safer, more effective and more personalized approach to cancer treatment.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|